Logo Image
|Articles|December 1, 2002

Oncology NEWS International

  • Oncology NEWS International Vol 11 No 12
  • Volume 11
  • Issue 12

EntreMed’s Thalidomide Analog in Phase I Multiple Myeloma Trial

ROCKVILLE, Maryland-En-treMed, Inc. has begun a phase I study of its thalidomide derivative ENMD 0995 at the Mayo Clinic, Rochester, Minnesota, in patients with multiple myeloma. ENMD 0995 recently received orphan drug designation from the FDA for the disease.

ROCKVILLE, Maryland—En-treMed, Inc. has begun a phase I study of its thalidomide derivative ENMD 0995 at the Mayo Clinic, Rochester, Minnesota, in patients with multiple myeloma. ENMD 0995 recently received orphan drug designation from the FDA for the disease.

The agent is a small molecular analog of thalidomide with improved angiogenesis inhibitor activity that, in animal models, does not show evidence of the toxic side effects reported for thalidomide, the company said in a news release.

Articles in this issue

almost 24 years ago

Tandem Transplants Increase CR, Reduce Treatment Mortality in Multiple Myeloma

almost 24 years ago

Stereotactic Radiosurgery Benefits Brain Met Patients

almost 24 years ago

Cancer Risk From Tainted Polio Vaccine Undetermined: IOM Report

almost 24 years ago

Tailored Messages Motivate Women to Get Mammograms

almost 24 years ago

Chemo/Rituximab Is Effective as First-Line CLL Therapy

almost 24 years ago

Preoperative Capecitabine/RT Downstages Rectal Cancer

almost 24 years ago

Intraoperative Lymphatic Mapping Enhances Cancer Staging

almost 24 years ago

Rituximab Ups Survival in Aggressive and Indolent NHL

almost 24 years ago

Genzyme Molecular Oncology Begins Kidney Cancer Vaccine Trial

almost 24 years ago

Lower Breast Cancer Survival in Hispanics: New Mexico Study

Related to this article

View more